Drugs / Trimethoprim/Sulfamethoxazole
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01595529 | May 2012 → Jun 2019 | urinary tract infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimethoprim/Sulfamethoxazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01595529 ↗ |
| Known as | TMP-SMX | “8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.” NCT01595529 ↗ |
| Route | Oral | “8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally” NCT01595529 ↗ |